IVPAF stock forecast, quote, news & analysis

IVPAF in upward trend: price rose above 50-day moving average on August 21, 2025

IVPAF moved above its 50-day moving average on August 21, 2025 date and that indicates a change from a downward trend to an upward trend. In of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 25, 2025. You may want to consider a long position or call options on IVPAF as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IVPAF just turned positive on August 25, 2025. Looking at past instances where IVPAF's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IVPAF advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 284 cases where IVPAF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where IVPAF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

IVPAF broke above its upper Bollinger Band on September 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IVPAF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.574) is normal, around the industry mean (22.009). P/E Ratio (34.069) is within average values for comparable stocks, (84.829). IVPAF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (8.064). IVPAF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.036). P/S Ratio (62.500) is also within normal values, averaging (315.384).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.